Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again).

Deighton CM, George E, Kiely PD, Ledingham J, Luqmani RA, Scott DG.

Rheumatology (Oxford). 2006 Jun;45(6):649-52. Epub 2006 Mar 9. No abstract available.

PMID:
16527881
2.

Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001).

Ledingham J, Deighton C; British Society for Rheumatology Standards, Guidelines and Audit Working Group.

Rheumatology (Oxford). 2005 Feb;44(2):157-63. Epub 2005 Jan 5. No abstract available. Erratum in: Rheumatology (Oxford). 2006 Sep;45(9):1170.

PMID:
15637039
3.
4.

Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe.

Emery P, Van Vollenhoven R, Ostergaard M, Choy E, Combe B, Graninger W, Krueger K, Matucci-Cerinic M, Navarro F, van Riel P, Settas L, Steinfeld S.

Ann Rheum Dis. 2009 Apr;68(4):456-9. doi: 10.1136/ard.2008.100362. No abstract available. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

PMID:
19286904
5.

[Proposal for anti-TNFalpha therapy in adult patients with rheumatoid arthritis].

Curković B, Babić-Naglić D, Morović-Vergles J, Anić B, Grazio S.

Reumatizam. 2007;54(1):16-9. Review. Croatian. Erratum in: Reumatizam. 2009;56(1):58.

PMID:
18450272
6.

[Proposal for anti-TNFalpha therapy in adult patients with rheumatoid arthritis].

Curković B, Babić-Naglić D, Morović-Vergles J, Anić B, Grazio S.

Reumatizam. 2008;55(1):22-5. Croatian. Erratum in: Reumatizam. 2009;56(1):58.

PMID:
19024266
7.

Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis.

Fautrel B, Pham T, Mouterde G, Le Loët X, Goupille P, Guillemin F, Ravaud P, Cantagrel A, Dougados M, Puéchal X, Sibilia J, Soubrier M, Mariette X, Combe B; Club Rhumatismes et Inflammation; Société Française de Rhumatologie.

Joint Bone Spine. 2007 Dec;74(6):627-37. Epub 2007 Oct 29.

PMID:
18037319
8.

BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies.

Ding T, Ledingham J, Luqmani R, Westlake S, Hyrich K, Lunt M, Kiely P, Bukhari M, Abernethy R, Bosworth A, Ostor A, Gadsby K, McKenna F, Finney D, Dixey J, Deighton C; Standards, Audit and Guidelines Working Group of BSR Clinical Affairs Committee; BHPR.

Rheumatology (Oxford). 2010 Nov;49(11):2217-9. doi: 10.1093/rheumatology/keq249a. Epub 2010 Sep 12. No abstract available.

PMID:
20837498
9.

The British Society for Rheumatology Biologics Register: 6 years on.

Hyrich KL, Watson KD, Isenberg DA, Symmons DP; BSR Biologics Register.

Rheumatology (Oxford). 2008 Oct;47(10):1441-3. doi: 10.1093/rheumatology/ken242. Epub 2008 Jul 1. No abstract available.

PMID:
18596052
10.

NICE guidelines on anti-tumor necrosis factor therapy for RA.

Scott DL, Steer S.

Nat Clin Pract Rheumatol. 2009 Jan;5(1):16-7. doi: 10.1038/ncprheum0964. Epub 2008 Dec 2. No abstract available.

PMID:
19048006
11.

[Statement of the German Society of Rheumatology (DGRh) reporting on the Institute's plan for biologicals in the second-line therapy for rheumatoid arthritis].

Braun J, Krüger K, Genth E.

Z Rheumatol. 2011 Dec;70(10):882-3. doi: 10.1007/s00393-011-0910-7. German. No abstract available.

PMID:
22139207
12.

If it works why can't we have it? Sequential anti-TNF therapy in the UK.

Deighton C.

Rheumatology (Oxford). 2010 Dec;49(12):2235-6. doi: 10.1093/rheumatology/keq257. Epub 2010 Aug 4. No abstract available.

PMID:
20685801
13.

The prevalence of patients with rheumatoid arthritis in the West Midlands fulfilling the BSR criteria for anti-tumour necrosis factor therapy: an out-patient study.

Yee CS, Filer A, Pace A, Douglas K, Situnayake D, Rowe IF; West Midlands Rheumatology Services and Training Committee.

Rheumatology (Oxford). 2003 Jul;42(7):856-9. Epub 2003 Mar 31.

PMID:
12730544
14.

UK consultant rheumatologists' access to biological agents and views on the BSR Biologics Register.

Kay LJ, Griffiths ID; BSR Biologics Register Management committee.

Rheumatology (Oxford). 2006 Nov;45(11):1376-9. Epub 2006 Oct 10.

PMID:
17040892
15.

[Recommendations for use of rituximab in patients with rheumatoid arthritis].

Rubbert-Roth A, Burmester GR, Dörner T, Gause A; Kommission Pharmakotherapie der DGRh.

Z Rheumatol. 2014 Mar;73(2):165-74. doi: 10.1007/s00393-013-1238-2. German.

PMID:
24659153
17.

Why do the French get much greater access to anti-TNF than the British? Vive la difference? Pas necessairement.

Deighton C, Hyrich K.

Rheumatology (Oxford). 2008 Nov;47(11):1600-2. doi: 10.1093/rheumatology/ken353. Epub 2008 Sep 10. No abstract available.

PMID:
18784124
18.

Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register.

Soliman MM, Hyrich KL, Lunt M, Watson KD, Symmons DP, Ashcroft DM; British Society for Rheumatology Biologics Register.

Arthritis Care Res (Hoboken). 2012 Aug;64(8):1108-15. doi: 10.1002/acr.21663.

19.

Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Hyrich KL, Watson KD, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register.

Rheumatology (Oxford). 2006 Dec;45(12):1558-65. Epub 2006 May 16.

PMID:
16705046
20.

Patients' perceptions of treatment with anti-TNF therapy for rheumatoid arthritis: a qualitative study.

Marshall NJ, Wilson G, Lapworth K, Kay LJ.

Rheumatology (Oxford). 2004 Aug;43(8):1034-8. Epub 2004 May 18.

PMID:
15150436

Supplemental Content

Support Center